Breaking News Instant updates and real-time market news.

AMD

AMD

$13.74

0.62 (4.73%)

, AMPH

Amphastar

$15.64

-0.02 (-0.13%)

17:46
09/20/17
09/20
17:46
09/20/17
17:46

On The Fly: After Hours Movers

HIGHER: AMD (AMD), up 6% after CNBC reported that Tesla (TSLA) was working with AMD on self-driving car AI chip... Amphastar Pharmaceuticals (AMPH), up 2.9% after receiving FDA approval for sodium bicarbonate injection... GSE Systems (GVP), up 3.5% after acquiring Absolute Consulting, which it said will be immediately accretive to earnings. LOWER AFTER EARNINGS: Herman Miller (MLHR), down 1.1% after reporting Q1 earnings, giving Q2 guidance... Dr Pepper Snapple Group (DPS), down 0.5% after cutting FY17 EPS guidance. ALSO LOWER: Juno Therapeutics (JUNO), down 4.2% after filing to sell $225M in common stock.

AMD

AMD

$13.74

0.62 (4.73%)

AMPH

Amphastar

$15.64

-0.02 (-0.13%)

GVP

GSE Systems

$2.80

0.05 (1.82%)

MLHR

Herman Miller

DPS

Dr Pepper Snapple

$91.68

-0.12 (-0.13%)

JUNO

Juno Therapeutics

$45.21

1.41 (3.22%)

  • 21

    Sep

  • 28

    Sep

AMD AMD
$13.74

0.62 (4.73%)

07/31/17
WELS
07/31/17
NO CHANGE
WELS
Wells Fargo downgrades Semiconductor sector to Market Weight
Wells Fargo analyst David Wong downgraded the Semiconductor sector to Market Weight from Overweight. Recent earnings reports from chip companies suggest that year-over-year growth will likely plateau or perhaps even decelerate over the next few months, Wong tells investors in a research note. He believes many chip stocks now have "elevated multiples" off calendar 2018 earnings estimates. Wong still sees good investment opportunities in some specific stocks, however, and reiterates Outperform ratings on Intel (INTC), Qualcomm (QCOM), Micron (MU), AMD (AMD), Skyworks (SWKS) and Microsemi (MSCC).
08/08/17
WELS
08/08/17
NO CHANGE
WELS
AMD competitive position has improved, says Wells Fargo
Wells Fargo says that AMD's "smooth execution on important new product introductions has significantly improved" its "competitive position in microprocessors and graphics chips." The firm quotes a third party researcher as saying that the company has started to gain share in server processors.
08/11/17
ROTH
08/11/17
NO CHANGE
Target $150
ROTH
Neutral
Roth says Nvidia 'stands alone' in semiconductors, valuation 'only question'
Roth Capital analyst Brian Alger said Nvidia's (NVDA) performance over the past several quarters has made it clear that neither Intel (INTC) nor AMD (AMD) have been able to slow the company's growth. Nvidia "stands alone" among semiconductor companies in terms of big volume and big dollar growth potential, but valuation of its stock remains the "only question," according to Alger. He raised his FY19 revenue estimate by roughly $1B and increased his price target on Nvidia shares to $150 from $120, but maintains a Neutral rating on the stock.
09/11/17
JEFF
09/11/17
NO CHANGE
JEFF
Jefferies lays out cryptocurrency exposure at Nvidia, AMD
Jefferies analyst Mark Lipacis estimates that in Q2, cryptocurrency revenues accounted for about 3% of quarterly sales for AMD (AMD) and about 10% for Nvidia (NVDA). The risk of a "crypto-driven" inventory correction driving material downside is low in the near term, Lipacis tells investors in a research note. He points out that cryptocurrency prices "increased materially" since bottoming in July. Further, both companies have introduced "cryptospecific GPU SKUs" that have a low risk of competing with core gaming GPUs in secondary markets, Lipacis writes. The analyst does not think cryptocurrencies are Fad. The technology they are based on, called Blockchain, supports secure accounting of distributed ledgers and has applications in financial services beyond cryptocurrencies, the analyst argues.
AMPH Amphastar
$15.64

-0.02 (-0.13%)

02/21/17
WELS
02/21/17
NO CHANGE
WELS
Outperform
Wells calls Amphastar CRL for naloxone spray 'disappointing and surprising'
Wells Fargo analyst David Maris said the fact that the FDA issued a Complete Response Letter, or CRL, to Amphastar on its nasal naloxone product was both "disappointing and surprising" given that the company currently markets the leading injectable generic naloxone. However, the stock's decline in pre-market trading "seems to more than reflect the nasal naloxone opportunity," added Maris, who keeps an Outperform rating on Amphastar shares, which are down 15% in early trading after the opening bell to $15.62.
07/21/17
WELS
07/21/17
NO CHANGE
WELS
Outperform
Amphastar 'David-vs-Goliath' win over Momenta a major victory, says Wells Fargo
Wells Fargo analyst David Maris said a jury's ruling that a Momenta (MNTA) patent was invalid and unenforceable is a very positive outcome for Amphastar (AMPH) in its "David-vs-Goliath-type" case. While he expects Momenta and partner Novartis' (NVS) Sandoz to appeal, Maris thinks this ruling puts Amphastar in a good position for any future potential settlement talks. Maris does not think investors should "count on any windfall" for Amphastar, but he does think, if approved, this could be an over $50M opportunity and keeps an Outperform rating on the stock, which is up 2% to $18.32 in afternoon trading.
03/14/17
03/14/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Corning (GLW) downgraded to Neutral from Buy at Goldman with analyst Doug Clark citing valuation with the stock up 33% since his upgrade back in April of 2016. The analyst keeps a $29 price target for the shares. 2. Amphastar (AMPH) downgraded to Outperform from Strong Buy at Raymond James with analyst Elliot Wilbur saying he sees an increased near-term risk profile following indications from FDA that Amphastar may have to withdraw its epinephrine product. 3. Abbott (ABT) downgraded to Market Perform from Outperform at BMO Capital. 4. GGP (GGP) downgraded to Neutral from Buy at UBS with analyst Jeremy Metz saying he does not see headwinds in the sector easing in the short term and cut his price target for GGP shares to $25 from $28. 5. Harmonic (HLIT) downgraded to Hold from Buy at Drexel Hamilton. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/14/17
RAJA
03/14/17
DOWNGRADE
Target $18
RAJA
Outperform
Amphastar downgraded to Outperform from Strong Buy at Raymond James
Raymond James analyst Elliot Wilbur downgraded Amphastar Pharmaceuticals to Outperform and lowered his price target for the shares to $18 from $21. The analyst sees an increased near-term risk profile following indications from FDA that Amphastar may have to withdraw its epinephrine product.
GVP GSE Systems
$2.80

0.05 (1.82%)

MLHR Herman Miller

03/23/17
RAJA
03/23/17
UPGRADE
RAJA
Market Perform
Herman Miller upgraded to Market Perform from Underperform at Raymond James
01/03/17
01/03/17
DOWNGRADE

Underperform
Herman Miller downgraded to Underperform at Raymond James
As previously reported, Raymond James downgraded Herman Miller to Underperform from Market Perform. Analyst Budd Bugatch said Herman Miller is the least attractive stock in the contract office furniture sub-sector given challenges in the North American business due to competitive pricing, raw material headwinds, and choppy order patterns. Further, the ELA business remains pressured by uncertainty in the U.K. and Middle East and DWR seems likely to face increased near-term pressures from per-opening expenses as it accelerates new studio openings. Bugatch cannot find a way to justify Herman Miller's current share price given near-term challenges.
03/23/17
03/23/17
UPGRADE

Market Perform
Herman Miller upgraded to Market Perform from Underperform at Raymond James
As previously reported, Raymond James upgraded Herman Miller to Market Perform from Underperform. Analyst Budd Bugatch views risk/reward a more balanced following the Q3 report.
06/27/17
SIDC
06/27/17
INITIATION
Target $38
SIDC
Buy
Herman Miller initiated with a Buy at Sidoti
Sidoti analyst Gregory Burns started Herman Miller with a Buy rating and $38 price target.
DPS Dr Pepper Snapple
$91.68

-0.12 (-0.13%)

06/07/17
BMOC
06/07/17
UPGRADE
BMOC
Outperform
Dr Pepper Snapple upgraded to Outperform from Market Perform at BMO Capital
05/16/17
05/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AIG (AIG) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Kai Pan citing the "strong" new Chief Executive Officer and attractive valuation. 2. Yum! Brands (YUM) upgraded to Buy from Hold at Argus with analyst John Staszak citing the company's decision to refranchise an additional 5% of its stores and institute additional cost cutting measures as reasons for the upgrade. 3. Dr Pepper Snapple (DPS) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Dara Mohsenian saying the company's organic sales growth is accelerating driven by an improved competitive outlook as Coca Cola (KO) and Pepsi (PEP) focus on using cash flow from the U.S. carbonated soft drink segment in high growth areas. 4. Regal Entertainment (RGC) upgraded to Buy from Hold at Loop Capital with analyst David Millerciting recent weakness in shares and has confidence the company will pay a special dividend to shareholders around the fourth quarter or in the first half of 2018. 5. Vipshop (VIPS) upgraded to Overweight from Neutral at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/07/17
BMOC
06/07/17
UPGRADE
BMOC
Outperform
Dr Pepper Snapple upgraded on valuation, earnings outlook at BMO Capital
As noted earlier, BMO Capital upgraded Dr Pepper Snapple to Outperform from Market Perform. Analyst Amit Sharma upgraded the stock based on valuation and his belief that its "attractive earnings growth outlook" makes its stock more likely to rise than a number of its peers' shares. He thinks that concerns about the sales growth of its Bai unit should dissipate. Target $105.
06/07/17
06/07/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ormat Technologies (ORA) upgraded to Overweight from Neutral at JPMorgan with analyst Paul Coster saying he believes the company is well positioned to continue posting revenue growth and margin expansion over the next few years. 2. Tenet (THC) upgraded to Outperform from Market Perform at Leerink. 3. Cott Corp. (COT) and Dr Pepper Snapple (DPS) were upgraded to Outperform from Market Perform at BMO Capital. 4. Sun Life Financial (SLF) upgraded to Outperform from Sector Perform at RBC Capital with analyst Darko Mihelic saying net flows and Assets Under Management at the company's MFS unit have improved over the last two months. He also notes that the stock has fallen about 12% since February. 5. Valvoline (VVV) upgraded to Buy from Neutral at Seaport Global with analyst Michael Harrison saying he expects the oil market to return to looser supply/demand and pricing to decline in the summer once Motiva completes its Port Arthur, TX turnaround in June, which would be a positive for Valvoline margins. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
JUNO Juno Therapeutics
$45.21

1.41 (3.22%)

08/31/17
STPT
08/31/17
DOWNGRADE
STPT
Reduce
Standpoint downgrades Juno after 50% rally in two weeks
Standpoint Research analyst Ronnie Moas downgraded Juno Therapeutics (JUNO) to Reduce from Buy noting that the shares are up more than 50% in the past two weeks. Despite Juno being a takeover target following Kite Pharma's (KITE) agreement this week to be sold to Gilead Sciences (GILD), positions should be trimmed at current share levels, Moas writes in an email. The analyst points out that Juno's market capitalization is over $4B even though no earnings are being generated. The stock in early trading is up 5%, or $1.98, to 42.27.
09/05/17
FBCO
09/05/17
NO CHANGE
FBCO
Outperform
No read through to Gilead, Kite from Cellectis clinical hold, says Credit Suisse
Credit Suisse analyst Alethia Young said the safety issues that Cellectis (CLLS) is encountering, and which prompted a clinical hold be placed on the company's allogenic CAR-T drug, UCART123, could be to some degree related to the company's platform. She adds that CRS, which led to a death in Cellectis' BPDCN study, is a known issue with CAR-T technologies and cases have been seen in Juno (JUNO) and Kite's (KITE) programs as well. The analyst, who doesn't think there is a read through to Kite and Gilead (GILD) from the Cellectis news and remains confident Kite will receive approval later this fall and launch Axi-Cel, keeps an Outpeform rating on Gilead shares.
09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
Juno Therapeutics initiated with an Overweight at Barclays
Barclays initiated Juno with an Overweight rating and a $55 price target, citing Juno's JCAR017 showing promising data with "a potentially better safety profile compared to the KITE/NVS programs," as well as Juno's pipeline having long-term upside.
08/31/17
STPT
08/31/17
DOWNGRADE
STPT
Reduce
Juno Therapeutics downgraded to Reduce from Buy at Standpoint Research

TODAY'S FREE FLY STORIES

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:23
10/20/17
10/20
17:23
10/20/17
17:23
Hot Stocks
Breaking Hot Stocks news story on Intellipharmaceutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:21
10/20/17
10/20
17:21
10/20/17
17:21
Hot Stocks
DBV Technologies: PEPITES trial does not reach primary endpoint »

DBV Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.92

1.17 (2.18%)

17:08
10/20/17
10/20
17:08
10/20/17
17:08
Periodicals
Regulator criticizes Wells Fargo over deceptive auto insurance program, NYT says »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

  • 07

    Nov

  • 29

    Nov

  • 15

    Jan

ALIM

Alimera Sciences

17:01
10/20/17
10/20
17:01
10/20/17
17:01
Syndicate
Alimera Sciences to sell $25M in shares in an 'at the market offering' »

On October 20, Alimera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$32.66

0.33 (1.02%)

16:51
10/20/17
10/20
16:51
10/20/17
16:51
Syndicate
Breaking Syndicate news story on Symantec »

Symantec files to sell 1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

EBMT

Eagle Bancorp

$19.55

0.15 (0.77%)

16:44
10/20/17
10/20
16:44
10/20/17
16:44
Hot Stocks
Breaking Hot Stocks news story on Eagle Bancorp »

EJF Capital reports 7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$11.26

1.99 (21.47%)

16:43
10/20/17
10/20
16:43
10/20/17
16:43
Hot Stocks
Breaking Hot Stocks news story on KalVista »

Longwood Fund II reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.19

0.002 (1.08%)

16:41
10/20/17
10/20
16:41
10/20/17
16:41
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$345.10

-6.71 (-1.91%)

16:40
10/20/17
10/20
16:40
10/20/17
16:40
Hot Stocks
Tesla amends 'warehouse agreements' to increase commitments to $1.1B »

On October 18,Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

SNV

Synovus

$47.30

0.54 (1.15%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Hot Stocks
Synovus CBO sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 15

    Nov

GTXI

GTx

$7.92

0.1 (1.28%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Syndicate
Breaking Syndicate news story on GTx »

GTx files to sell 8.77M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

, BKMU

BankMutual

$10.80

0.55 (5.37%)

16:36
10/20/17
10/20
16:36
10/20/17
16:36
Conference/Events
BankMutual to host special shareholder meeting »

Special Shareholder…

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

BKMU

BankMutual

$10.80

0.55 (5.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CNXR

Connecture

$0.49

-0.01 (-2.00%)

16:35
10/20/17
10/20
16:35
10/20/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Connecture »

Connecture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$23.83

0.25 (1.06%)

, PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

16:31
10/20/17
10/20
16:31
10/20/17
16:31
General news
On The Fly: Top stock stories for Friday »

Stocks opened sharply…

GE

General Electric

$23.83

0.25 (1.06%)

PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

SNCR

Synchronoss

$11.39

-0.12 (-1.04%)

IL

Bought by SNCR

SKX

Skechers

$33.99

9.96 (41.45%)

PYPL

PayPal

$70.97

3.72 (5.53%)

NCR

NCR Corp.

$33.05

-4 (-10.80%)

LHO

LaSalle Hotel

$28.52

-1.94 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 29

    Nov

  • 30

    Nov

16:30
10/20/17
10/20
16:30
10/20/17
16:30
Options
Preliminary option volume of 22.9M today »

Preliminary option volume…

MKL

Markel

$1,078.23

14.88 (1.40%)

, SNC

State National

$21.05

0.02 (0.10%)

16:26
10/20/17
10/20
16:26
10/20/17
16:26
Conference/Events
State National to host special shareholder meeting »

Special Shareholder…

MKL

Markel

$1,078.23

14.88 (1.40%)

SNC

State National

$21.05

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

RYTM

Rhythm Pharmaceuticals

$23.08

-0.17 (-0.73%)

16:22
10/20/17
10/20
16:22
10/20/17
16:22
Hot Stocks
Breaking Hot Stocks news story on Rhythm Pharmaceuticals »

Orbimed Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.